Results of a phase III study examining zanubrutinib combined with rituximab compared to bendamustine and rituximab for first line treatment of mantle cell lymphoma.
Home / Resource Library / A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma